Herr H W, Sheinfeld J
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
J Urol. 1997 Oct;158(4):1331-4.
Carcinoma in situ is present in the contralateral testis in up to 5% of patients with a primary germ cell tumor and will progress in the majority of cases to a second primary invasive cancer. We address the question of whether the other testis should be biopsied in patients with testis tumors.
The literature on carcinoma in situ of the testis from 1972 to the present was critically evaluated in an attempt to address the issue of carcinoma in situ in the opposite testis.
Carcinoma in situ of the opposite testis in patients with a primary germ cell tumor is easily diagnosed by biopsy and cured by orchiectomy or radiation. The problem is that biopsy is unnecessary in the majority of patients, and treatment of carcinoma in situ may have undesirable physical and emotional consequences. The rare patient who has an asynchronous second primary cancer can be cured with current treatment regimens.
We do not advocate nor does the literature support routine biopsy of the opposite testis in patients with unilateral testis tumor. Patient education and close followup are rational alternatives to intervention in all cases to diagnose a small subset who are risk for bilateral tumors.
在原发性生殖细胞肿瘤患者中,高达5%的患者对侧睾丸存在原位癌,且在大多数情况下会进展为第二原发性浸润癌。我们探讨睾丸肿瘤患者的对侧睾丸是否应进行活检这一问题。
对1972年至今有关睾丸原位癌的文献进行严格评估,以试图解决对侧睾丸原位癌的问题。
原发性生殖细胞肿瘤患者对侧睾丸的原位癌通过活检易于诊断,并可通过睾丸切除术或放疗治愈。问题在于,大多数患者无需进行活检,且原位癌的治疗可能会产生不良的身体和情感后果。患有异时性第二原发性癌症的罕见患者可通过当前的治疗方案治愈。
我们不主张对单侧睾丸肿瘤患者常规活检对侧睾丸,文献也不支持这样做。在所有病例中,患者教育和密切随访是诊断双侧肿瘤风险较小亚组的合理替代干预措施。